NeoPharm, Inc.’s IL13-PE38QQR (IL13-PE) has been granted orphan drug designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Orphan drug designation provides seven years of market exclusivity for IPF upon approval, as well as a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of FDA user fees and certain tax credits. Dr. Aquilur Rahman, president and chief executive officer, said, “IPF is the most d...